Skip to main content
Premium Trial:

Request an Annual Quote

Michael Wyzga

Exact Sciences has increased the size of its board to 10 directors and appointed Michael Wyzga to fill the spot. Wyzga will serve as a Class III director and be on Exact's audit committee until the firm's 2015 annual meeting. Between 2011 and 2013, he was the president and CEO of Radius Health, where he was also a board member. Prior to that, he held various management positions at Genzyme. Wyzga currently is a director at Akebia Therapeutics and Oncomed Pharmaceuticals.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.